{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.1","upperLimit":"93.2","value":"88.1"},{"groupId":"OG001","lowerLimit":"77.3","upperLimit":"90.6","value":"84.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"description":"Disease control rate was the percentage of participants who achieved confirmed sCR, CR, VGPR, PR, minimal response (MR) or have demonstrated stable disease (SD) for at least 12 weeks prior to any evidence of progression. PD was development of or an increase in the size of bone lesions or soft tissue plasmacytomas. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \\<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry/fluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \\<100 mg/24 hr; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\<200 mg/24 hours. The data cutoff date was July 9, 2018.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"Pembrolizumab+Pomalidomide+Dexamethasone"},{"description":"Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG001","title":"Standard of Care (SOC) Pomalidomide+Dexamethasone"}],"paramType":"NUMBER","populationDescription":"The analysis population included all randomized participants. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 30 months","title":"Disease Control Rate (DCR) Evaluated According to the IMWG Response Criteria by CAC Blinded Central Review","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}